Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Marketing Safety Study of Optivate in Severe Haemophilia A
NCT01811875Phase 4Terminated
- Sponsor
- Bio Products Laboratory
- Start
- Nov 2014
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 4 trial of factor viii + von Willebrand factor in hemophilia A, sponsored by Bio Products Laboratory. Started Nov 2014; status: terminated.
02
Drugs
factor viii + von Willebrand factor
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT01811875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01811875.